[go: up one dir, main page]

MX2013006353A - Metodos y composiciones utiles para promover el sueño en animales. - Google Patents

Metodos y composiciones utiles para promover el sueño en animales.

Info

Publication number
MX2013006353A
MX2013006353A MX2013006353A MX2013006353A MX2013006353A MX 2013006353 A MX2013006353 A MX 2013006353A MX 2013006353 A MX2013006353 A MX 2013006353A MX 2013006353 A MX2013006353 A MX 2013006353A MX 2013006353 A MX2013006353 A MX 2013006353A
Authority
MX
Mexico
Prior art keywords
animal
methods
animals
compositions useful
sleep
Prior art date
Application number
MX2013006353A
Other languages
English (en)
Inventor
Brian Michael Zanghi
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2013006353A publication Critical patent/MX2013006353A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fodder In General (AREA)

Abstract

Se proporcionan métodos y composiciones para promover el sueño en un animal. En un aspecto general, una cantidad promotora del sueño de astaxantina y una cantidad promotora del sueño de melatonina se administran juntas a un animal. La astaxantina se puede administrar en una cantidad que varíe de aproximadamente 0.1 a aproximadamente 60 mg/kg/peso corporal del animal. La melatonina se puede administrar en una cantidad que varíe de aproximadamente 0.1 a aproximadamente 40 mg/kg/peso corporal del animal. El método puede comprender además administrar conjuntamente una cantidad promotora del sueño de zinc al animal. El zinc puede ser administrado en una cantidad que varíe de aproximadamente 10 a aproximadamente 100 mg/kg/de peso corporal del animal.
MX2013006353A 2010-12-07 2011-11-14 Metodos y composiciones utiles para promover el sueño en animales. MX2013006353A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45918110P 2010-12-07 2010-12-07
PCT/US2011/060597 WO2012078317A1 (en) 2010-12-07 2011-11-14 Methods and compositions useful for promoting sleep in animals

Publications (1)

Publication Number Publication Date
MX2013006353A true MX2013006353A (es) 2013-08-26

Family

ID=46207452

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006353A MX2013006353A (es) 2010-12-07 2011-11-14 Metodos y composiciones utiles para promover el sueño en animales.

Country Status (11)

Country Link
US (1) US20130273176A1 (es)
EP (1) EP2648513A4 (es)
JP (1) JP2014505031A (es)
CN (1) CN103228139A (es)
AU (1) AU2011338846B2 (es)
BR (1) BR112013016554A2 (es)
CA (1) CA2819595A1 (es)
MX (1) MX2013006353A (es)
RU (1) RU2594876C2 (es)
WO (1) WO2012078317A1 (es)
ZA (1) ZA201305086B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2014054651A1 (ja) * 2012-10-03 2016-08-25 富士フイルム株式会社 睡眠改善剤、ノンレム睡眠時間増加剤及び鎮静剤
JPWO2015099102A1 (ja) * 2013-12-27 2017-03-23 富士フイルム株式会社 亜鉛含有睡眠改善剤、ノンレム睡眠時間増加剤及び鎮静剤
CN110882245A (zh) * 2019-12-16 2020-03-17 厦门市健康医疗大数据中心(厦门市医药研究所) 一种改善睡眠的组合物及其用途
ES2837877A1 (es) * 2019-12-31 2021-07-01 Laboratorios Vinas S A Composicion galenica, para uso oral, liquida, que comprende melatonina y una sal de zinc y metodo y uso correspondientes
KR102682447B1 (ko) * 2021-06-29 2024-07-04 주식회사 엘지생활건강 히노키티올을 함유하는 구강용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0951842B1 (en) * 1999-01-20 2002-12-04 N.V. Nutricia Infant formula
US7211280B1 (en) * 1999-09-09 2007-05-01 Nestec S.A. Condition of elderly pets
ATE406882T1 (de) * 2000-05-16 2008-09-15 Suntory Ltd Zusammensetzungen zur normalisierung des zirkadianen rythmus
US20020120001A1 (en) * 2000-10-13 2002-08-29 Ashni Naturaceuticals, Inc. Compositions containing tryptamines, cartenoids and tocotrienols and having synergistic antioxidant effect
US6974841B1 (en) * 2002-09-27 2005-12-13 Rapisarda Family Irrevocable Trust Pet anti-aging wellness supplement
US20050249785A1 (en) * 2003-08-13 2005-11-10 Gordon John G Use of melatonin-containing oral supplement with animals
WO2005058064A1 (ja) * 2003-12-19 2005-06-30 Menicon Co., Ltd. アスタキサンチン配合ペット用食物
WO2005097101A1 (ja) * 2004-04-06 2005-10-20 Taiyokagaku Co., Ltd. 睡眠改善用組成物
EP2007368A2 (en) * 2006-04-04 2008-12-31 Hill's Pet Nutrition Inc. Compositions and methods for enhancing the antioxidant status of animals
ES2593880T3 (es) * 2009-09-11 2016-12-13 Nestec, S.A. Composiciones y métodos para mejorar las funciones cognitivas y relacionadas en animales

Also Published As

Publication number Publication date
AU2011338846B2 (en) 2016-04-14
RU2013131098A (ru) 2015-01-20
ZA201305086B (en) 2014-12-23
BR112013016554A2 (pt) 2016-07-12
AU2011338846A1 (en) 2013-06-13
WO2012078317A1 (en) 2012-06-14
CN103228139A (zh) 2013-07-31
CA2819595A1 (en) 2012-06-14
EP2648513A1 (en) 2013-10-16
JP2014505031A (ja) 2014-02-27
RU2594876C2 (ru) 2016-08-20
US20130273176A1 (en) 2013-10-17
EP2648513A4 (en) 2014-04-30

Similar Documents

Publication Publication Date Title
MX2010002392A (es) Composiciones de brimonidina mejoradas para tratar eritema.
NZ595987A (en) A novel formulation of diclofenac
NZ722319A (en) A novel formulation of meloxicam
PH12013500923A1 (en) Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
NZ706990A (en) A veterinary method of alleviating noise aversion
MX2013006353A (es) Metodos y composiciones utiles para promover el sueño en animales.
AU2016216741A1 (en) Compositions and methods of use of an inappetance-controlling compound
NZ595798A (en) Ectoparasiticidal methods and formulations
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
MX2013013098A (es) Metodos y composiciones para fomentar el crecimiento de la masa corporal magra.
MY160509A (en) Adiponectin production accelerating composition
MX2013014430A (es) Metodos para reducir neurodegeneracion.
WO2012134590A3 (en) Calcium supplement
WO2013052433A3 (en) Methods and compositions for reducing food intake and body weight gain in animals
MX2013012990A (es) Metodos y composiciones para preservar la masa corporal magra durante la perdida de peso.
RU2011134662A (ru) Способ предотвращения развития стрессовых реакций в организме животных
RU2009121969A (ru) Способ предотвращения развития стрессовых реакций в организме животных
TH143143A (th) วิธีและองค์ประกอบที่มีประโยชน์สำหรับชักนำให้สัตว์นอนหลับ
UA67215U (ru) Способ создания модели отравления крыс наночастицами свинца
UA42066U (ru) Способ лечения телят при эймериозно-стронгилоидозной инвазии
UA56367U (en) composition neuroactive preparation
WO2007064547A3 (en) Morinda citrifolia based formulation and methods for weight management
UA55533U (ru) Ажених тваринспособ профилактики нарушений морфофункциональных свойств тканей печени в онтогенезе потомков гамма-облученных и подвергнутых стрессу животных
RU2010146367A (ru) Способ моделирования экспериментального амилоидоза у животных
UA67214U (ru) Способ выведения свинца из организма животных